Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Syndax Pharmaceuticals

04/08/2026 22:01

Syndax Pharmaceuticals Inc SNDX.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -83 cents.  The mean expectation of twelve analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -67 cents to -33 cents per share.
Revenue rose 91.8% to $72.79 million from a year ago; analysts expected $79.32 million. 
Syndax Pharmaceuticals Inc's reported EPS for the quarter was a loss of 55 cents​.
The company reported a quarterly loss of $49.36 million.
Syndax Pharmaceuticals Inc shares had fallen by 12.0% this quarter and lost 8.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $37.00, about 48% above its last closing price of $19.24
This summary was machine generated from LSEG data August 4 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.44
-0.55
Missed
Mar. 31 2026 
-0.58
-0.48
Beat
Dec. 31 2025 
-0.58
-0.78
Missed
Sep. 30 2025 
-0.72
-0.70
Beat